Neurothera Labs Inc.
NTLX.V
TSX
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -32.63% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -32.63% | ||||
| Cost of Revenue | -22.86% | ||||
| Gross Profit | -36.75% | ||||
| SG&A Expenses | 198.85% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 697.58% | ||||
| Operating Income | -2,530.85% | ||||
| Income Before Tax | -4,240.43% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -4,260.64% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -4,005.32% | ||||
| EBIT | -2,530.85% | ||||
| EBITDA | -5,167.39% | ||||
| EPS Basic | -25.69% | ||||
| Normalized Basic EPS | -- | ||||
| EPS Diluted | -25.69% | ||||
| Normalized Diluted EPS | -- | ||||
| Average Basic Shares Outstanding | -- | ||||
| Average Diluted Shares Outstanding | 34.12% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||